Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Hepatitis C: Current Controversies and Future Potential in Solid Organ Transplantation

Hepatitis C: Current Controversies and Future Potential in Solid Organ Transplantation Purpose of Review To highlight the changing landscape of hepatitis C virus (HCV) infection in the context of organ transplantation. This focuses on areas of controversy and future potential in the era of highly effective direct-acting antiviral (DAA) agents. Recent Findings Since the advent of safe and highly effective DAA therapy, HCV infection is now curable in virtually all cases, including organ transplant recipients. Excellent drug tolerability and safety combined with high cure rates across all organ groups means that HCV is no longer a barrier to transplantation or its outcomes. Mounting data demonstrate the safety of using organs from HCV-infected donors with subsequent treatment of HCV in the recipient and a potential to expand the donor pool. Summary Historical data demonstrating inferior survival in transplant recipients with HCV is of limited relevance in the DAA era. Virtually all transplant recipients with HCV infection can be cured, while early data also suggest excellent outcomes in recipients of organs from HCV viremic donors. The optimal timing of HCV therapy in relation to transplantation and the optimal use of organs from HCV viremic donors remain areas of controversy and ongoing research efforts. . . . . . Keywords Hepatitis C Liver http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Infectious Disease Reports Springer Journals

Hepatitis C: Current Controversies and Future Potential in Solid Organ Transplantation

Loading next page...
 
/lp/springer_journal/hepatitis-c-current-controversies-and-future-potential-in-solid-organ-VuVcclyL0y
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Infectious Diseases
ISSN
1523-3847
eISSN
1534-3146
DOI
10.1007/s11908-018-0625-x
Publisher site
See Article on Publisher Site

Abstract

Purpose of Review To highlight the changing landscape of hepatitis C virus (HCV) infection in the context of organ transplantation. This focuses on areas of controversy and future potential in the era of highly effective direct-acting antiviral (DAA) agents. Recent Findings Since the advent of safe and highly effective DAA therapy, HCV infection is now curable in virtually all cases, including organ transplant recipients. Excellent drug tolerability and safety combined with high cure rates across all organ groups means that HCV is no longer a barrier to transplantation or its outcomes. Mounting data demonstrate the safety of using organs from HCV-infected donors with subsequent treatment of HCV in the recipient and a potential to expand the donor pool. Summary Historical data demonstrating inferior survival in transplant recipients with HCV is of limited relevance in the DAA era. Virtually all transplant recipients with HCV infection can be cured, while early data also suggest excellent outcomes in recipients of organs from HCV viremic donors. The optimal timing of HCV therapy in relation to transplantation and the optimal use of organs from HCV viremic donors remain areas of controversy and ongoing research efforts. . . . . . Keywords Hepatitis C Liver

Journal

Current Infectious Disease ReportsSpringer Journals

Published: May 22, 2018

There are no references for this article.